# Agios Pharmaceuticals, Inc. clinical trials: 52 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials with Agios Pharmaceuticals, Inc. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Agios Pharmaceuticals, Inc.: 52 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/agios-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07859423 | A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera | Agios Pharmaceuticals, Inc. | Phase 2/3 | Not yet recruiting | Polycythemia Vera | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859423) |
| June 18, 2026 | NCT07656415 | A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) | Agios Pharmaceuticals, Inc. | Phase 3 | Recruiting | Sickle Cell Disease | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656415) |
| April 8, 2026 | NCT07517133 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or... | Agios Pharmaceuticals, Inc. | Phase 3 | Recruiting | Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517133) |
| April 2, 2026 | NCT07506863 | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha... | Agios Pharmaceuticals, Inc. | Phase 3 | Recruiting | Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07506863) |
| November 21, 2025 | NCT07241234 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria | Agios Pharmaceuticals, Inc. | Phase 1 | Recruiting | Phenylketonuria | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241234) |
| July 20, 2025 | NCT07075640 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy... | Agios Pharmaceuticals, Inc. | Phase 1 | Active not recruiting | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07075640) |
| April 13, 2025 | NCT06924970 | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) | Agios Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | Sickle Cell Disease | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06924970) |
| December 20, 2024 | NCT06745271 | A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available... | Agios Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Participants | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06745271) |
| October 18, 2024 | NCT06648824 | Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants | Agios Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06648824) |
| February 29, 2024 | NCT06286046 | A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy | Agios Pharmaceuticals, Inc. | Phase 2 | Withdrawn | Sickle Cell Disease, Nephropathy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06286046) |
| February 29, 2024 | NCT06286033 | Single and Multiple Ascending Dose Study and Food Effect Study for AG181 | Agios Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06286033) |
| March 21, 2023 | NCT05777993 | A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study | Agios Pharmaceuticals, Inc. | Phase 4 | Enrolling by invitation | Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05777993) |
| November 9, 2022 | NCT05610657 | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With... | Agios Pharmaceuticals, Inc. | Phase 1 | Completed | Moderate Hepatic Impairment | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05610657) |
| August 5, 2022 | NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Agios Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | Myelodysplastic Syndromes | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05490446) |
| January 3, 2022 | NCT05175105 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not... | Agios Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05175105) |
| December 3, 2021 | NCT05144256 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly... | Agios Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05144256) |
| September 2, 2021 | NCT05031780 | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | Agios Pharmaceuticals, Inc. | Phase 2/3 | Active not recruiting | Sickle Cell Disease | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05031780) |
| August 6, 2021 | NCT04995315 | Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008 | Agios Pharmaceuticals, Inc. | Observational | Completed | Pyruvate Kinase Deficiency | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04995315) |
| July 16, 2021 | NCT04964323 | Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) | Agios Pharmaceuticals, Inc. | Observational | Terminated | Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia, Anemia, Hemolytic | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04964323) |
| February 25, 2021 | NCT04770779 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | Agios Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04770779) |
| February 25, 2021 | NCT04770753 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or... | Agios Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04770753) |
| January 6, 2021 | NCT04696393 | A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in... | Agios Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04696393) |
| September 25, 2020 | NCT04565678 | A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants | Agios Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04565678) |
| September 3, 2020 | NCT04536792 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With... | Agios Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers, Anemia, Sickle Cell | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04536792) |
| July 15, 2020 | NCT04472832 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants | Agios Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04472832) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 29 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 10 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 31 |
| Active not recruiting | 10 |
| Recruiting | 4 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
| Approved for marketing | 1 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pyruvate Kinase Deficiency of Red Cells | 10 |
| Anemia, Sickle Cell | 6 |
| Anemia, Hemolytic | 5 |
| Anemia | 5 |
| Anemia, Hemolytic, Congenital Nonspherocytic | 3 |
| Thalassemia | 2 |
| Myelodysplastic Syndromes | 2 |
| Lymphoma | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Hematologic Diseases | 2 |
| Metabolic Diseases | 2 |
| Polycythemia Vera | 1 |
| Kidney Diseases | 1 |
| Phenylketonurias | 1 |
| Hematologic Neoplasms | 1 |
| Hodgkin Disease | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma, T-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Bathroom remodelers in the United States](https://specstream.ai/data/businesses/bathroom-remodelers/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Nicaraguan restaurants in the United States](https://specstream.ai/data/businesses/nicaraguan-restaurants/united-states)
- [Textile manufacturers in the United States](https://specstream.ai/data/businesses/textile-manufacturers/united-states)
- [Burger restaurants in the United States](https://specstream.ai/data/businesses/burger-restaurants/united-states)
